{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:56:02Z","timestamp":1754261762945},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,10]]},"DOI":"10.7759\/cureus.10368","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T23:09:03Z","timestamp":1599779343000},"source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of Patterns and Correlations of the Degree of Conjunctival Hyperemia Induced by Omidenepag Isopropyl 0.002% and Ripasudil 0.4%"],"prefix":"10.7759","author":[{"given":"Etsuko","family":"Terao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Nakakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saki","family":"Dote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Tabuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Kiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61423-7","article-title":"Glaucoma","volume":"377","author":"Quigley HA","year":"2011","unstructured":"Quigley HA. Glaucoma. Lancet. 2011, 377:1367-1377. 10.1016\/S0140-6736(10)61423-7","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1016-1","article-title":"Omidenepag isopropyl ophthalmic solution 0.002%: first global approval","volume":"78","author":"Duggan S","year":"2018","unstructured":"Duggan S. Omidenepag isopropyl ophthalmic solution 0.002%: first global approval. Drugs. 2018, 78:1925-1929. 10.1007\/s40265-018-1016-1","journal-title":"Drugs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000001221","article-title":"Phase 2, randomized, dose-finding studies of omidenepag isopropyl, a selective ep2 agonist, in patients with primary open-angle glaucoma or ocular hypertension","volume":"28","author":"Aihara M","year":"2019","unstructured":"Aihara M, Lu F, Kawata H, et al.. Phase 2, randomized, dose-finding studies of omidenepag isopropyl, a selective ep2 agonist, in patients with primary open-angle glaucoma or ocular hypertension. J Glaucoma. 2019, 28:375-385. 10.1097\/IJG.0000000000001221","journal-title":"J Glaucoma"},{"key":"ref4","article-title":"A phase 3 trial comparing omidenepag isopropyl 0.002% with latanoprost 0.005% in primary open-angle glaucoma and ocular hypertension: the AYAME study","volume":"59","author":"Lu FH","year":"2018","unstructured":"Lu FH, Aihara M, Kawata H, et al.. A phase 3 trial comparing omidenepag isopropyl 0.002% with latanoprost 0.005% in primary open-angle glaucoma and ocular hypertension: the AYAME study. Invest Ophthalmol Vis Sci. 2018, 59:","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref5","unstructured":"Santen. (2020). Accessed. July 9, 2020: https:\/\/www.santen.co.jp\/medical-channel\/di\/safety\/DI050_safety_eybelis.pdf."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-012-0188-6","article-title":"Korean Glaucoma Compliance Study Group: noncompliance with glaucoma medication in Korean patients: a multicenter qualitative study","volume":"57","author":"Park MH","year":"2013","unstructured":"Park MH, Kang KD, Moon J. Korean Glaucoma Compliance Study Group: noncompliance with glaucoma medication in Korean patients: a multicenter qualitative study. Jpn J Ophthalmol. 2013, 57:47-56. 10.1007\/s10384-012-0188-6","journal-title":"Jpn J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.323","article-title":"Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115","volume":"131","author":"Tanihara H","year":"2014","unstructured":"Tanihara H, Inoue T, Yamamoto T, K-115 Clinical Study Group, et al.. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2014, 131:1288-1295. 10.1001\/jamaophthalmol.2013.323","journal-title":"JAMA Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.05.016","article-title":"Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension","volume":"156","author":"Tanihara H","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, K-115 Clinical Study Group, et al.. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013, 156:731-736. 10.1016\/j.ajo.2013.05.016","journal-title":"Am J Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.0525","article-title":"Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials","volume":"133","author":"Tanihara H","year":"2015","unstructured":"Tanihara H, Inoue T, Yamamoto T, K-115 Clinical Study Group, et al.. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol. 2015, 133:755-761. 10.1001\/jamaophthalmol.2015.0525","journal-title":"JAMA Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12599","article-title":"Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study","volume":"93","author":"Tanihara H","year":"2015","unstructured":"Tanihara H, Inoue T, Yamamoto T, K-115 Clinical Study Group, et al.. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015, 93:254-260. 10.1111\/aos.12599","journal-title":"Acta Ophthalmol"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2020-000538","article-title":"Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4%","volume":"5","author":"Terao E","year":"2020","unstructured":"Terao E, Nakakura S, Fujisawa Y, et al.. Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4%. BMJ Open Ophthalmol. 2020, 5:000538.","journal-title":"BMJ Open Ophthalmol"},{"key":"ref12","unstructured":"Declaration of Helsinki. (2020). Accessed. 08\/04\/2020: https:\/\/www.wma.net\/what-we-do\/medical-ethics\/declaration-of-helsinki\/.."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.12.004","article-title":"Japanese guidelines for allergic conjunctival diseases. Japanese Society of Allergology","volume":"66","author":"Takamura E","year":"2017","unstructured":"Takamura E, Uchio E, Ebihara N, et al.. Japanese guidelines for allergic conjunctival diseases. Japanese Society of Allergology. Allergol Int. 2017, 66:220-229. 10.1016\/j.alit.2016.12.004","journal-title":"Allergol Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2018.1554153","article-title":"Hyperemia analysis software for assessment of conjunctival hyperemia severity","volume":"44","author":"Yoneda T","year":"2019","unstructured":"Yoneda T, Sumi T, Hoshikawa Y, et al.. Hyperemia analysis software for assessment of conjunctival hyperemia severity. Curr Eye Res. 2019, 44:376-380. 10.1080\/02713683.2018.1554153","journal-title":"Curr Eye Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-011-0107-2","article-title":"Automated hyperemia analysis software: reliability and reproducibility in healthy subjects","volume":"56","author":"Yoneda T","year":"2012","unstructured":"Yoneda T, Sumi T, Takahashi A, et al.. Automated hyperemia analysis software: reliability and reproducibility in healthy subjects. Jpn J Ophthalmol. 2012, 56:1-7. 10.1007\/s10384-011-0107-2","journal-title":"Jpn J Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.05.052","article-title":"Stimulation of prostanoid IP and EP(2) receptors dilates retinal arterioles and increases retinal and choroidal blood flow in rats","volume":"570","author":"Mori A","year":"2007","unstructured":"Mori A, Saito M, Sakamoto K, et al.. Stimulation of prostanoid IP and EP(2) receptors dilates retinal arterioles and increases retinal and choroidal blood flow in rats. Eur J Pharmacol. 2007, 570:135-141. 10.1016\/j.ejphar.2007.05.052","journal-title":"Eur J Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/40187","article-title":"Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension","volume":"389","author":"Uehata M","year":"1997","unstructured":"Uehata M, Ishizaki T, Satoh H, et al.. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997, 389:990-994. 10.1038\/40187","journal-title":"Nature"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a021401","article-title":"The small GTPase Rho: cellular functions and signal transduction","volume":"120","author":"Narumiya S","year":"1996","unstructured":"Narumiya S. The small GTPase Rho: cellular functions and signal transduction. J Biochem. 1996, 120:215-228. 10.1093\/oxfordjournals.jbchem.a021401","journal-title":"J Biochem"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-13157","article-title":"AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia","volume":"55","author":"Van de Velde S","year":"2014","unstructured":"Van de Velde S, Van Bergen T, Sijnave D, et al.. AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014, 55:1006-1016. 10.1167\/iovs.13-13157","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/39585-evaluation-of-patterns-and-correlations-of-the-degree-of-conjunctival-hyperemia-induced-by-omidenepag-isopropyl-0002-and-ripasudil-04","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:22:59Z","timestamp":1707506579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/39585-evaluation-of-patterns-and-correlations-of-the-degree-of-conjunctival-hyperemia-induced-by-omidenepag-isopropyl-0002-and-ripasudil-04"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.10368","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,10]]}}}